Opportunities and Benefits of CETA for Canada’s Pharmaceutical Exporters

Why export to the EU?

How will CETA benefit Canadian pharmaceutical companies?

Opportunities for investment in Canada’s pharmaceutical sector through CETA

Canada is an attractive destination for pharmaceutical research and manufacturing, offering:

Once CETA is provisionally applied:

Mutual recognition of pharmaceutical good manufacturing practices

Labour mobility

Government procurement

Top 5 suppliers of pharmaceutical products to the EU% of Import Market Share
Source: Eurostat (2016)
United States42.6%
Switzerland35.6%
Israel4.0%
Singapore3.7%
China3.0%
Canada (8th)1.5%

Once CETA is provisionally applied, Canadian exporters of pharmaceutical products will enjoy the advantages created from the agreement over competitors based in countries that do not have a preferential trade agreement in force with the EU.

Non-CETA related factors to keep in mind when exporting pharmaceutical products to the EU

For more detail on how CETA benefits your company, contact a Trade Commissioner today.

Date Modified: